Monopar Therapeutics (NASDAQ:MNPR) Stock Price Down 12.3% - Here's What Happened

Key Points

• Monopar Therapeutics' stock price dropped 12.3%, trading as low as $93.37 before closing at $88.54.
• Analysts have mixed ratings on the stock, with target prices ranging from $87.00 to $115.00, indicating a Moderate Buy average rating.
• Insiders have sold a significant number of shares, with total sales amounting to $36.7 million over the past ninety days.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report)'s share price fell 12.3% during trading on Friday . The stock traded as low as $93.37 and last traded at $88.54. 131,570 shares traded hands during mid-day trading, an increase of 194% from the average session volume of 44,825 shares. The stock had previously closed at $100.96.

Analyst Ratings Changes

Several research firms recently commented on MNPR. Oppenheimer set a $115.00 target price on Monopar Therapeutics and gave the stock an "outperform" rating in a research note on Thursday, October 2nd. Cantor Fitzgerald restated an "overweight" rating on shares of Monopar Therapeutics in a research report on Wednesday, September 24th. Weiss Ratings restated a "sell (d-)" rating on shares of Monopar Therapeutics in a report on Wednesday. BTIG Research increased their target price on Monopar Therapeutics from $87.00 to $104.00 and gave the stock a "buy" rating in a research report on Thursday, September 25th. Finally, Piper Sandler set a $95.00 target price on Monopar Therapeutics and gave the company an "overweight" rating in a research note on Thursday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Monopar Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $97.33.

Monopar Therapeutics Stock Down 11.2%

The company's 50 day moving average price is $53.18 and its two-hundred day moving average price is $42.93. The stock has a market cap of $553.11 million, a P/E ratio of -26.92 and a beta of 1.42.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.12. As a group, equities research analysts forecast that Monopar Therapeutics Inc. will post -1.65 earnings per share for the current year.

Insiders Place Their Bets

In other Monopar Therapeutics news, Director Christopher M. Starr sold 16,800 shares of the company's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the sale, the director directly owned 5,173 shares of the company's stock, valued at approximately $206,920. This represents a 76.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $356,160.00. Following the sale, the director directly owned 11,486 shares in the company, valued at approximately $459,440. The trade was a 43.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 592,733 shares of company stock valued at $36,700,227. Company insiders own 20.50% of the company's stock.

Institutional Trading of Monopar Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Gerber LLC purchased a new stake in shares of Monopar Therapeutics in the 1st quarter valued at approximately $204,000. AlphaQuest LLC acquired a new position in Monopar Therapeutics in the first quarter valued at $44,000. Affinity Asset Advisors LLC acquired a new position in shares of Monopar Therapeutics during the first quarter worth about $2,257,000. OMERS ADMINISTRATION Corp purchased a new stake in Monopar Therapeutics during the first quarter worth about $328,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Monopar Therapeutics in the first quarter valued at about $673,000. Institutional investors and hedge funds own 1.83% of the company's stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.